Alzinova AB
The answer first
Does Alzinova beat the market?
No, Alzinova has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 50% of Nordic stocks
- Quality89
- Value62
- Trend6
No. 62 of 195 in healthcare
Max for seven days
Follow Alzinova with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 20 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Alzinova
Your first answer is free, no account needed.
Do you own Alzinova, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Alzinova and a few more. Free, no card.
Super Stock+46.4%In short
- Alzinova has fallen 78.7% over the past year, including dividends.
- Overall, Alzinova ranks better than 50% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 92.9%. The price is 98.5% below its peak now.
What do analysts think of Alzinova?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 50% of Nordic stocks.
No. 62 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 36 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.01
- Asset turnoverSales divided by everything the company owns0.03
- Return on equityProfit divided by equity−14.8%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 26 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.4
- P/SPrice divided by sales15.3
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 171 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−58.2%
- 6 months−27.8%
- 9 months−50.0%
- 12 months−78.7%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Alzinova
One fund we follow owns Alzinova. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Alzinova
Alzinova AB is a company in healthcare, listed on Nasdaq Stockholm. By market value, Alzinova is number 100 of 137 companies in healthcare on Nasdaq Stockholm. Alzinova has not paid a dividend in the past twelve months. Of the three measures in the ranking, Alzinova is strongest on quality, better than 89% of Nordic stocks. The share trades in SEK. It has around 7 employees.
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study.


See the full analysis of Alzinova.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card